Episode Summary
Executive Summary: The episode explores Epoch Biodesign’s mission to solve the plastic waste problem by engineering enzymes that break down unrecyclable plastics into valuable platform chemicals. The conversation ties plastic’s environmental burden to climate emissions, explains why recycling is structurally limited, and argues that biology plus modern compute can create scalable, lower-carbon industrial processes and a broader biodesign platform.
Main Topics: The scale and history of the plastics problem (Priority: 5/5): Jason and Jacob frame plastics as a modern, post-World War II phenomenon that has grown into a massive global material flow with serious waste, pollution, and climate consequences. Why plastic recycling fails at scale (Priority: 5/5): Jacob explains that plastics are diverse, contaminated, and often downcycled, making high-quality recycling expensive and technologically difficult; most material never becomes true circular feedstock. Epoch Biodesign’s enzyme-based process (Priority: 5/5): Epoch uses engineered enzymes in a cell-free fermentation process to convert unrecyclable plastic into industrial chemicals, aiming to handle waste while generating saleable outputs. Climate and industrial emissions impact (Priority: 4/5): The discussion highlights that the biggest climate benefit may come from replacing fossil-derived chemical production, not just diverting plastic from landfill or incineration. Biology as a programmable technology platform (Priority: 4/5): Epoch’s broader thesis is that advances in machine learning, automation, DNA tools, and protein engineering can make biology a general-purpose platform for solving climate and environmental problems. Business model, IP strategy, and scaling path (Priority: 4/5): Epoch intends to build and validate early facilities, own the core IP, then license the technology to larger industrial partners rather than remain a capital-intensive chemical manufacturer. Team, funding, and company-building journey (Priority: 3/5): Jacob describes founding the company in high school, partnering with systems biology expert Doug Kell, and raising seed capital to expand R&D capacity and scale the science.
Key Arguments: Plastic is ubiquitous, relatively new, and has grown into a systemic waste and climate problem rather than a simple materials issue. Most plastics are not truly recycled; they are sorted poorly, downcycled, burned, landfilled, or leaked into the environment. Biology can convert plastic waste into the same platform chemicals currently made from fossil carbon, potentially reducing emissions and waste simultaneously. A cell-free enzyme process is preferable to living microbes because it avoids contamination risk, reduces process complexity, and can improve carbon efficiency. The largest emissions reduction may come from replacing energy-intensive fossil chemical production with low-energy biocatalysis. Modern tools such as machine learning, automation, CRISPR, DNA synthesis, and improved sequencing are enabling faster biological design cycles than were possible even a decade ago. Epoch’s strategy is to own the IP, demonstrate unit economics at meaningful scale, and then license the process to industrial customers for broader deployment.
Data Points: Community size: more than 1,300 members - MCJ membership Slack community described in the opening sponsor message Plastic production growth outlook: quadrupled 2015 levels by 2050 - Jacob cites projected growth in plastic production if current trends continue Plastic recycling rate: 9% - Referenced as a commonly cited statistic, though Jacob notes reporting can be misleading Seed round size: $11 million - Epoch Biodesign’s initial seed financing Carbon reduction potential: about 75% - Jacob says some conservative examples show chemicals made via Epoch’s process can have roughly 75% lower CO2e than incumbent fossil-derived routes Scale target for early commercialization: 10 to 20,000 ton range - Planned scale for Epoch’s initial process before shifting toward licensing Government funding for enabling tools: over £10 million - Doug Kell’s prior work developing biology design tools Human Genome Project funding: $3 billion - Used to illustrate the scale of investment behind modern biological measurement tools
Pivotal Quotes: "Biology is the original circular economy." — Jacob Nathan: Describing why biology is a powerful framework for sustainable industrial processes "For every one ton of plastic that we put in, because there's some very interesting chemistry that's happening, we actually get potentially more than one ton of product out." — Jacob Nathan: Explaining the economics and chemistry advantages of the enzyme-based process "The path we're on is one of quadrupled 2015 levels by 2050." — Jacob Nathan: Summarizing the projected scale of the plastic production problem
Implications: If Epoch succeeds, plastic waste could become a feedstock for low-carbon chemicals, reducing both pollution and fossil dependence. More broadly, the episode suggests climate tech winners may increasingly come from biology, AI, and automation working together.